Subchronic Toxicity of Atorvastatin, a Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitor, in Beagle Dogs

Toxicologic Pathology

Volumn 24, Issue 4, 1996, Pages 468-476

  Walsh, Kathleen M ^a   Albassam, Mudher A ^a   Clarke, David E ^a  

^a PFIZER INC   (United States)

Author keywords

brain; cholesterol; Lipid regulation; liver; skeletal muscle

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL METABOLISM; DOG; DOSE RESPONSE; DRUG EFFECT; HISTOPATHOLOGY; HYPERLIPIDEMIA; LIVER BIOPSY; LIVER TOXICITY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TOXICITY TESTING; WEIGHT REDUCTION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DOGS; EATING; ENZYME INHIBITORS; FEMALE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LENS, CRYSTALLINE; LEUKOCYTE COUNT; LIPOPROTEINS; MALE; MICROSCOPY, ELECTRON; MUSCLE, SKELETAL; PYRROLES;

ANIMALIA; CANIS FAMILIARIS; ORYCTOLAGUS CUNICULUS;

EID: 0029834473     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339602400409     Document Type: Article

References (21)

1. Alberts AW, MacDonald JS, Till AE, and Tobert JA (1989). Lovastatin. Cardiovascular Drug Rev. 7: 89-109.
2. Berry PH, MacDonald JS, Alberts AW, Molon-Noblot S., Chen JS, Lo CYL, Greenspan MD, Allen H., Durand-Cavagna G., Jensen R., Bailly Y., Delort P., and Duprat P. (1988). Brain and optic system pathology in hypocholesterolemic dogs treated with a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am. J. Pathol. 132: 427-443.
3. Bocan TMA, Ferguson E., McNally W., Uhlendorf PD, Mueller SB, Dehart P., Sliskovic DR, Roth BD, Krause BR, and Newton RS (1992). Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors. Biochim. Biophys. Acta 1123: 133-144.
4. Farnsworth WH, Hoeg JM, Maher M., Brittain EH, Sherins RJ, and Brewer HB (1987). Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (Mevinolin) or neomycin. J. Clin. Endocrinol. Metab. 65: 546-550.
5. Fukami M., Maeda N., Fukushige J., Kogure Y., Shimada Y., Ogawa T., and Tsujita Y. (1993). Effects of HMG-CoA reducatase inhibitors on skeletal muscle of rabbits. Res. Exp. Med. 193: 263-273.
6. Gerson RJ, Allen HL, Lankas GR, MacDonald JS, Alberts AW, and Bokelman DL (1991). The toxicity of a fluorinated-biphenyl HMG-CoA reductase inhibitor in beagle dogs. Fund. Appl. Toxicol. 16: 320-329.
7. Gerson RJ, MacDonald JS, Alberts AW, Chen J., Yudkovitz JB, Greenspan MD, Rubin LF, and Bokelman DL (1990). On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp. Eye Res. 50: 65-78.
8. Gerson RJ, MacDonald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ, and Bokelman DL (1989). Animal safety and toxicology of simvastatin and related hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am. J. Med. 87: 28S-38S.
9. Hockwin O., Evans M., Roberts SA, and Stoll RE (1990). Postmortem biochemistry of beagle dog lenses after treatment with fluvastatin (Sandoz) for 2 years at different dose levels. Lens Eye Toxic. Res. 7: 563-575.
10. Kojima M., Hockwin O., Rao GS, and Garcia J. (1990). Investigations on the presence of 3-hydroxy-3-methylglutaryl coenzyme A reductase in lenses of various animals species. Lens Eye Toxic. Res. 7: 605-623.
11. MacDonald JS, Gerson RJ, Kornbrust DJ, Kloss MW, Prahalada S., Berry PH, Alberts AW, and Bokelman DL (1988). Preclinical evaluation of lovastatin. Am. J. Cardiol. 62: 16J-27J.
12. Manabe S., Sudo S., Yamashita K., Miyakoshi N., Matsunuma N., Tanase H., and Masuda H. (1989). Subacute toxicological study in monkeys treated orally with pravastatin sodium for 5 weeks. J. Toxicol. Sci. 14: 57-83.
13. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, and Black DM (1995). Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. 15: 678-682.
14. Okolicsanyi L., Lirussi F., Strazzabosco M., Jemmolo RM, Orlando R., Nassuato G., Muraca M., and Grepaldi G. (1986). The effect of drugs on bile flow and composition. An overview. Drugs 31: 430-438.
15. Owen K., Pick SEL, and Adams MJ (1994). Toxicity of a novel HMG-CoA reductase inhibitor in the common marmoset. Hum. Exp. Toxicol. 13: 357-368.
16. Sigler RE, Dominick MA, and McGuire EJ (1992). Subacute toxicity of a halogenated pyrrole hydroxymethylglutaryl-coenzyme A reductase inhibitor in Wistar rats. Toxicol. Pathol. 20: 595-602.
17. Sliskovic DR, Roth BD, and Bocan TMA (1992). Tissue selectivity of HMG-CoA reductase inhibitors. DN&P 5: 517-533.
18. Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germershausen JI, Vyas KP, Kari PH, and MacDonald JS (1991). HMG-CoA reductase inhibitor-induced myopathy in the rat: Cyclosporine A interaction and mechanism studies. J. Pharm. Exper. Therap. 257: 1225-1235.
19. Sonada Y., Gotow T., Kuriyama M., Nakahara K., Arimura K., and Osame M. (1994). Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle & Nerve 17: 891-897.
20. Tarumi C., Matsunumo N., Miyakoshi N., Yamashita K., and Masuda H. (1989). Long term oral administration study of pravastatin sodium to beagles for 104 weeks. J. Toxicol. Sci. 14: 85-101.
21. Tobert JA (1987). New developments in lipid-lowering therapy: The role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation 76: 534-538.